Nina Bauer, PhD, MBA, Merck KGaA, Darmstadt, Germany, describes CRISPR-Cas 9 technology and its uses in advanced therapies. The enzymes utilized in CRISPR-Cas 9 is an efficient method of genome editing and is quicker and simpler than viral vectors. The technology can be applied in off-the-shelf therapies for solid tumors, where genome editing is necessary to reduce immunogenicity and to integrate the chimeric antigen receptor (CAR) onto the cell. This interview took place at Advanced Therapies Week 2022.
Nina Bauer, PhD, MBA is an employee of Merck KGaA.